ML 007/muscarinic antagonist - MapLight Therapeutics
Alternative Names: ML-007/muscarinic antagonist combination tablet - MapLight Therapeutics; ML-007/PAC; ML-007C-MALatest Information Update: 02 Apr 2024
At a glance
- Originator MapLight Therapeutics
- Class Antipsychotics
- Mechanism of Action Muscarinic M1 receptor agonists; Muscarinic M4 receptor agonists; Muscarinic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Psychotic disorders; Schizophrenia